Skip to main content

Syndax Pharmaceuticals Inc (SNDX)

Sector
Biotechnology
Last price
$9.20
As of

Kresmion compiles this page from SNDX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Syndax Pharmaceuticals Inc (SNDX): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-02.

As of . Source: SEC EDGAR filings for SNDX. Method and limitations.

COMPANY DOSSIER

See the full SNDX dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for SNDX on one page. Preview it with sample data, then open it live with a free account.

Preview the SNDX dossier

Active events for SNDX

FREE, NO ACCOUNT

Every event on SNDX, as it fires

You are seeing 5 of 10 events recorded on SNDX since 2026-06-05.

The five above landed across 3 days. The other 5 were recorded on 2 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

SNDX positions held by the managers we follow (2026Q3)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported value
RENAISSANCE TECHNOLOGIES LLC FundCUSIP 87164F105 · 2026Q3$3.6M0.00%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, SNDX

More data on SNDX

SNDX against its peers

SNDX's operating margin of -158.4% ranks in the 21st percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricSNDXPeer medianPercentilen
Revenue FY172M USD107M USD6311
Operating margin-158.4%-10.1%2111
Net margin-165.6%-15.1%2111
Return on equity-441.6%-33.7%315
1 year-44.9%11.6%915

Peers (17): RIGL, IRWD, GLUE, MGTX, ARDX, ORIC, LXRX, PRME, CRVS, SLDB, TBPH, PHAR, AURA, JANX, SGMT, XOMA.D, NVCT. Left out: LTGO (no annual filing), CTY (no annual filing), BBTX (no annual filing), OBX (no annual filing), IVA (period gap), AKTS (no annual filing), ODTX (no annual filing), ATTO (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (SNDX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

Cite this data

Kresmion counts the managers it follows that reported a non-option position in SNDX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on SNDX in the last 180 days.

Upstream: SEC EDGAR filings for SNDX

Kresmion, "Syndax Pharmaceuticals Inc (SNDX) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/SNDX. Upstream data: SEC EDGAR filings for SNDX.

Link to this data (HTML):

<a href="https://kresmion.com/research/SNDX">Syndax Pharmaceuticals Inc (SNDX) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow SNDX on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to SNDX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the SNDX dossier
Share

The SNDX intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.